The bond market has entered a financial twilight zone, and at this point, there doesn't seem to be a smooth way out.Market Insiderread more
President Donald Trump believes he has quite the bargaining chip with the European Union.Marketsread more
Some Apple employees have become disillusioned with the group's culture, where some have thrived while others feel sidelined.Technologyread more
President Donald Trump renewed calls Tuesday of re-admitting Russia to the G7 ahead of the group's summit in Biarritz, France this weekend.Politicsread more
Urban Outfitters reported earnings and same-store sales for the second quarter that beat analyst expectations, while revenue fell short.Retailread more
Biden has shown staying power at the top of a jammed Democratic field even as polling numbers for Sanders, Warren and Harris wax and wane.2020 Electionsread more
The FDIC on Tuesday votes to approve a five-agency revision of the post-crisis regulation known as the Volcker Rule.Financeread more
The yield curve is the only economic indicator pointing to a recession, according to Credit Suisse.Marketsread more
Amid fears of a recession, Domino's Pizza CEO Ritch Allison said Tuesday that the U.S. consumer is still strong.Restaurantsread more
Another former J.P. Morgan precious metals traders pleaded guilty Tuesday to criminal charges of manipulating the precious metals markets.Wall Streetread more
The Dow Jones Industrial Average fell for the first time in four sessions as recession fears lingered.US Marketsread more
Celgene's shares fell about 6.3 percent in after-hours trading on Thursday after the pharmaceutical company said that it won't initiate a phase 3 trial for a Crohn's disease drug.
The company said it made the decision after a recommendation from the data monitoring committee, which assessed overall benefit and risk. There were no meaningful safety imbalances identified, Celgene said.
"While we are disappointed with the results of REVOLVE, we remain committed to advancing our portfolio of novel medicines for patients suffering from this disease and other inflammatory bowel disorders," Celgene President and Chief Operating Officer Scott Smith said in a statement.
Celgene said it would review the full dataset from the phase two trial of an ulcerative colitis drug before determining the next steps.